Clinical trials: Esophagogastric Junction
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT01939275
- Testing
- copper Cu 64-DOTA-trastuzumab, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma
- Trial name
- NCT01260701
- Testing
- Akt Inhibitor MK2206
- Where
- 187 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Neoplasms, Esophageal Diseases
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
- Trial name
- OSI3650 (NCT00442507)
- Testing
- Erlotinib, Avastin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Stomach Neoplasms
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07920224
- Testing
- candonilimab combined with fruquintinib and paclitaxel albumin-bound
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced…
- Trial name
- NCT04891900
- Testing
- TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric…
- Trial name
- NCT07043400
- Testing
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin
- Where
- 95 sites in United States, Argentina and 14 more
- Volunteers
- 351 people
- Sponsor
- BeOne Medicines
Gastric Cancer, GastroEsophageal Cancer
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care.
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06243757
- Testing
- MDASI-GI
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the recommended Phase 2 dose (RP2D) and the safety and tolerability profile along with preliminary signs…
- Trial name
- NCT03707028
- Testing
- Rivoceranib, Paclitaxel
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Elevar Therapeutics
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma…
- Trial name
- NCT04704934
- Testing
- Trastuzumab deruxtecan, Ramucirumab, Paclitaxel
- Where
- 156 sites in Argentina, Belgium and 22 more
- Volunteers
- 490 people
- Sponsor
- Daiichi Sankyo
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of a modified neoadjuvant immunotherapy plus chemotherapy (one cycle of Tislelizumab monotherapy followed by four cycles of…
- Trial name
- TRACE (NCT06469060)
- Testing
- neoadjuvant anti-PD-1 with DOC chemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai Chest Hospital
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer. This study includes two arms: A and B.
- Trial name
- NCT05246982
- Testing
- HLX07+HLX10+oxaliplatin+capecitabine, HLX07
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Henlius Biotech
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
This clinical trial test whether taking part in a diet support intervention will help with patients nutrition and quality of life after surgery for esophagus or stomach cancer.
- Trial name
- NCT05203627
- Testing
- Best Practice, Questionnaire Administration, Telemedicine Visit
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
- Trial name
- NCT00098527
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of Esophagogastric Junction
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric…
- Trial name
- NICLA (NCT05505461)
- Testing
- neoadjuvant Radiation plus SOX and PD-1 antibody
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University People's Hospital
Fluorescence Laparoscopy, Adenocarcinoma of the Esophagogastric Junction
The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction
The fluorescent laparoscopic technique would be applied to the radical resection of gastric cancer at the junction of esophagus and stomach, and compared with the traditional laparoscopic radical resection of gastric cancer to…
- Trial name
- NCT03647540
- Testing
- fluorescent laparoscopic radical gastrectomy, traditional laparoscopic radical gastrectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Dong Yang
Gastric Cancer
CKD-702 Plus Irinotecan in Gastric Cancer
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR).
- Trial name
- NCT05750290
- Testing
- CKD-702 in combination with irinotecan
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
Carcinoma, Gastrointestinal Diseases
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma.
- Conditions
- Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
- Trial name
- EXPLORING (NCT05494060)
- Testing
- Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Cancer, Gastric Cancer
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer.
- Trial name
- NCT02283359
- Testing
- Selinexor, Irinotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
This phase II trial tests how well concentrating heated (hyperthermic) chemotherapy in the area that contains the abdominal organs (intraperitoneal [IP]) at the time of surgery works in treating patients with gastric or…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07139951
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.